Associations among socioeconomic status (SES), patterns of care and outcomes in breast cancer (BC) patients (pts) in a universal health care system: Ontario’s experience.

Authors

null

Alexander Kumachev

University of Toronto, Toronto, ON, Canada

Alexander Kumachev , Maureen E. Trudeau , Kelvin K. Chan

Organizations

University of Toronto, Toronto, ON, Canada, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Research Funding

No funding sources reported

Background: The Canadian health care system was designed to provide equitable access to equivalent standards of care. We aim to examine if BC pts with different SES received different care and had different overall survival (OS) in Ontario, Canada’s largest province. Methods: Female pts diagnosed with BC between 2003-2009 were identified from the Ontario Cancer Registry and linked to databases related to physician claims, hospital and emergency visits and provincial funding programs to ascertain demographics, cancer stage (CS), comorbidities, mammography use, surgery type, adjuvant chemotherapy (chemo), radiation (RT), and vital statistics. SES was defined as neighbourhood income by postal code attained from Statistics Canada and divided into income quintiles (Q1-Q5; Q5=highest). Univariate and multivariable analyses were used to examine the association between i) SES and mammogram screening and BC treatments, and ii) SES and OS. Results: 34,446 BC pts with CS available were identified. 76.0% were > 50 years old. The proportion of CS I, II, III and IV were, 41.4, 38.8, 14.9, & 4.9%, respectively. Screening mammograms (1-5 years prior to diagnosis) rates were significantly higher with higher SES (Q5 = 50.1% and Q1=41.7% (OR = 1.43, 95% CI: 1.32-1.56, p<0.0001)) for pts age >55. Pts with higher SES were more likely to be diagnosed at an earlier CS (p<0.0001, Q5=44.3% & Q1=37.7% were diagnosed with CS (OR = 1.31, 1.23-1.41)). Pts with higher SES were more likely to receive adjuvant chemo (p<0.0001, Q5 vs. Q1 OR = 1.18, 1.10-1.26) and RT (p<0.0001, Q5 vs. Q1 OR = 1.24, 1.15-1.33). There were no obvious differences in adjuvant trastuzumab (T-mab) use (p=0.62), breast conserving surgery (p=0.057) and time between surgery and adjuvant chemo (p=0.15) based on SES. The 5 year OS rates for Q1-Q5 were 80.0, 81.0, 82.2, 83.9 & 85.7%, respectively (p<0.0001). After adjusting for age, CS, comorbidities, rural residence, use of adjuvant chemo, T-mab, RT and surgery type, higher SES remained associated with better OS (p=0.0017). Conclusions: Higher SES is associated with more use of screening and treatments, and better OS in BC pts in a universal health care system.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research

Track

Health Services Research

Sub Track

Outcomes and Quality of Care

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 6625)

DOI

10.1200/jco.2014.32.15_suppl.6625

Abstract #

6625

Poster Bd #

88

Abstract Disclosures

Similar Abstracts